Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 6, Issue 3, Pages 219-230Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1083-8791(00)70004-8
Keywords
varicella-zoster virus; hematopoietic cell transplantation; latency; immunosuppression
Categories
Funding
- NCI NIH HHS [P01-CA49605] Funding Source: Medline
- NIAID NIH HHS [AI36884, AI20459] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P01CA049605] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036884, R21AI036884, R01AI020459] Funding Source: NIH RePORTER
Ask authors/readers for more resources
New information about the mechanisms of varicella-zoster virus (VZV) pathogenesis and the host response to the virus has improved our understanding of the threat that VZV reactivation may pose after hematopoietic cell transplantation (HCT). Antiviral therapy compensates for some of the deficiencies in VZV immunity in HCT recipients, and inactivated varicella vaccine may be useful for the early reconstitution of adaptive immunity to VZV after HCT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
